PDS Planning Inc boosted its position in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,964 shares of the medical equipment provider’s stock after acquiring an additional 496 shares during the period. PDS Planning Inc’s holdings in Boston Scientific were worth $287,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Aspire Private Capital LLC lifted its position in Boston Scientific by 10.9% during the 4th quarter. Aspire Private Capital LLC now owns 7,885 shares of the medical equipment provider’s stock worth $456,000 after acquiring an additional 773 shares during the last quarter. California Public Employees Retirement System lifted its position in Boston Scientific by 3.0% during the 4th quarter. California Public Employees Retirement System now owns 3,798,511 shares of the medical equipment provider’s stock worth $219,592,000 after acquiring an additional 112,222 shares during the last quarter. Jennison Associates LLC lifted its position in Boston Scientific by 1.3% during the 4th quarter. Jennison Associates LLC now owns 1,227,833 shares of the medical equipment provider’s stock worth $70,981,000 after acquiring an additional 15,596 shares during the last quarter. Commerzbank Aktiengesellschaft FI bought a new position in shares of Boston Scientific during the 4th quarter worth about $366,000. Finally, Cetera Trust Company N.A bought a new position in shares of Boston Scientific during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 89.07% of the company’s stock.
Insider Activity
In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock valued at $3,418,529 over the last three months. 0.50% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on BSX
Boston Scientific Price Performance
BSX opened at $68.99 on Wednesday. Boston Scientific Co. has a one year low of $48.35 and a one year high of $69.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The company’s 50 day simple moving average is $67.39 and its 200-day simple moving average is $60.19. The stock has a market capitalization of $101.22 billion, a P/E ratio of 64.48, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78.
Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The business had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.59 billion. During the same period in the prior year, the firm earned $0.45 earnings per share. Sell-side analysts anticipate that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
- Five stocks we like better than Boston Scientific
- Trading Stocks: RSI and Why it’s Useful
- 3 Technologies to Challenge NAND Flash Dominance in AI
- Trading Halts Explained
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- Investing in the High PE Growth Stocks
- Packaging Corporation of America: Buy The Dip
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.